Literature DB >> 16807519

Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms.

Wikrom Karnsakul1, Thaschawee Arkachaisri, Kanit Atisook, Wanee Wisuthsarewong, Yudhtana Sattawatthamrong, Prapun Aanpreung.   

Abstract

Vanishing bile duct syndrome (VBDS) is a rare disorder and requires a liver biopsy for a diagnosis. The condition has not been reported in children with toxic epidermal necrolysis (TEN). The etiology of VBDS in our patient with TEN is most likely from drug hypersensitivity. A high index of suspicion will prompt clinicians to start more specific investigations and treatments. The use of immunosuppressive agents, intravenous immunoglobulin and ursodeoxycholic acid has not been consistently successful in these patients. A new approach with biologic agents such as anti-tumor necrosis factor-alpha may be a promising therapy and reduce severe adverse outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807519

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  4 in total

Review 1.  Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.

Authors:  Jason C White; Stephanie Appleman
Journal:  Pediatrics       Date:  2014-09-22       Impact factor: 7.124

2.  Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience.

Authors:  Ayesha S Siddique; Osama Siddique; Michael Einstein; Eva Urtasun-Sotil; Saverio Ligato
Journal:  World J Hepatol       Date:  2020-05-27

3.  Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis in an infant.

Authors:  Hye-young Kim; Hea Kyoung Yang; Seong Heon Kim; Jae Hong Park
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

Review 4.  Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).

Authors:  E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.